Eric Ashman, MD
Neurology · Soldotna, AKNPI 1639160849
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Harmony Biosciences LLC at 41.8% of the total. Reporting peaked in 2019 at $267 and has fallen 83.1% since, to $45 in 2024. That places this record below the midpoint for neurology clinicians in AK, where the typical reported total is $2,594.
Across 70 payments — averaging $9.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$276
- Supernus Pharmaceuticals, Inc.$165
- Jazz Pharmaceuticals Inc.$74
- Eisai Inc.$64
- Resmed Corp$32
- Abbott$27
- plus $23 from 1 others
What the payments were for
- Food & beverage$61693%
- Education$457%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 25 | $276 |
| Supernus Pharmaceuticals, Inc. | 36 | $165 |
| Jazz Pharmaceuticals Inc. | 4 | $74 |
| Eisai Inc. | 2 | $64 |
| Resmed Corp | 1 | $32 |
| Abbott | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
How this compares
$661 in reported general payments places this provider in the 30th percentile of 21 neurology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 22 | $95,720 |
| UbrelvyUbrogepant | 30 | $72,681 |
| Lamictal XrLamotrigine | 13 | $47,533 |
| QuliptaAtogepant | 35 | $39,053 |
| BriviactBrivaracetam | 25 | $38,766 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $37,844 |
| VimpatLacosamide | 14 | $18,935 |
| Nurtec OdtRimegepant Sulfate | 14 | $17,661 |
| Lamotrigine ErLamotrigine | 35 | $13,778 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $7,428 |
| Gabapentin | 177 | $5,143 |
| Entacapone | 23 | $3,922 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 25 | $2,527 |
| Pregabalin | 84 | $2,254 |
| Lacosamide | 24 | $2,005 |
Paid to pharmacies, not to this prescriber.
Other neurology in Soldotna
- Kristen JessenSoldotna$51K
- Naomi ArensonSoldotna$4K
- Anne McDonoughSoldotna$0
- Stanford DownsAnchorage$19K
- Mary DownsAnchorage$17K
- John KellyWasilla$13K
- Peter OsterbauerEagle River$12K
- Jeffrey SponslerWasilla$8K
- Scot HinesAnchorage$8K
- David HenzlerAnchorage$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.